CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,110 enrolled
Drug / intervention
Tazarotene Cream 0.1% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02886715
NCT02886715Phase 3Completed
CompareCT.gov

A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris

Fougera Pharmaceuticals Inc.·interventional·Posted Sep 1, 2016·Updated Aug 17, 2018

In Brief

A Phase 3 clinical trial evaluating Tazarotene Cream 0.1%, Tazorac®, and 1 other intervention for Acne Vulgaris. Completed, enrolled 1,110 participants across 25 sites.

Detailed Summary

A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 1, 2016
Enrollment StartSep 21, 2016
Primary CompletionMay 31, 2017
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 9.8 years ago

Interventions

Tazarotene Cream 0.1%drug

Tazarotene Cream 0.1% applied to cover the affected areas of the face once daily for 84 +/- 4 days.

Tazorac®drug

Tazorac® applied to cover the affected areas of the face once daily for 84 +/- 4 days.

Placebodrug

Placebo (vehicle of the test product) applied to cover the affected areas of the face once daily for 84 +/- 4 days.